Cidara Announces Appointment of Chrysa Mineo as Independent Director
March 01, 2018 16:05 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, March 01, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the...
Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results
February 27, 2018 16:32 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
Cidara Provides Corporate Update and Reports Third Quarter 2017 Financial Results
November 08, 2017 16:01 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
Cidara Therapeutics to Report Third Quarter 2017 Financial Results and Provide Corporate Update
November 01, 2017 16:05 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will...
Cidara Therapeutics Announces Pricing of $20 Million Private Placement of Common Stock
October 19, 2017 09:00 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the pricing...
Cidara Provides Corporate Update and Reports Second Quarter 2017 Financial Results
August 09, 2017 16:31 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
Cidara Provides Corporate Update and Reports First Quarter 2017 Financial Results
May 10, 2017 17:06 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, May 10, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
March 15, 2017 17:22 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, March 15, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
Cidara Therapeutics Reports Unfavorable Results of Phase 2 RADIANT Trial of CD101 Topical in VVC
February 21, 2017 07:30 ET
|
Cidara Therapeutics, Inc.
Further Development of CD101 Topical for VVC to be discontinued CD101 IV development program in candidemia and invasive candidiasis (including Phase 2 STRIVE trial) continuing and remains on track ...
Cidara Therapeutics Announces Closing of Public Offering of Common Stock, Including Exercise of Underwriter’s Option to Purchase Additional Shares
October 13, 2016 09:20 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Oct. 13, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the closing...